

Simcyp Leadership is Unmatched

- Created a renowned technology for virtualizing R&D and accelerating the development of hundreds of novel drugs
- Built a unique consortium of 36 major biopharmaceutical companies, contributing to innovation in PBPK and mechanistic modeling
- Educated hundreds of scientists across commercial, academic, and regulatory organizations
- Provided numerous grants to academic scientific teams including Simcyp licenses at no cost to hundreds of academic institutions
- Groundbreaking use of PBPK in regulatory filings including >200 label claims using modeling & simulation in lieu of clinical trials



Thank You

Thank you to the consortium members for partnering with Simcyp and Certara during these past 20 years. Together, we have advanced the science of drug development through modeling & simulation.


- Steve Toon

A handwritten signature in black ink, likely belonging to Steve Toon.

Abbvie, Amgen, Astellas, Astra Zeneca, Biogen, Bristol-Myers Squibb, Celgene, Daiichi- Sankyo, Eisai, Eli Lilly, Gilead, GSK, Grünenthal, Idorsia, Incyte, Johnson & Johnson, Kyowa Kirin, Lundbeck, Merck, Merck Serono, Mitsubishi Tanabe, Nektar, Novartis, Ono, Otsuka, Pfizer, Roche/Genentech/Chugai, Sanofi Aventis, Servier, Shionogi, Shire, Sumitomo Dainippon/Sunovion, Taisho, Takeda, UCB, Vertex

Simcyp:

20 Years of Innovation



CERTARA

Categories

Historical Facts

Grants awarded to Simcyp


Product innovation

Customer education


Regulatory support

Drug development milestones

Grant & Partnership Scheme: Awards given by Simcyp



Prof. Amin Rostami delivering a lecture on 'Demystifying the Path for PBPK Applications'



Hands-on Simcyp workshop: The intersection of science, software and drug development